Accueil > Actualité
Actualite financiere : Actualite bourse

Valneva: article on Lyme vaccine in The Lancet

( - Valneva reports that the results of two Phase II clinical trials on its Lyme disease vaccine candidate, VLA15 (the subject of a collaboration agreement with Pfizer), have been published in the medical journal Lancet Infectious Diseases.

These trials, together with a third Phase II trial in pediatric participants, supported the design of the ongoing pivotal Phase III trial VALOR (Vaccine Against Lyme for Outdoor Recreationists), the vaccine company points out.

Pfizer plans to submit a marketing authorisation application to the US FDA, and another marketing authorization application to the European Medicines Agency in 2026, subject to positive data.

Copyright (c) 2024 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.